Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract with a significant placebo response.
SUMMARY Background
Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract with a significant placebo response.
Aim
To conduct a systematic review and meta-analysis examining the magnitude of placebo response rate in treatment trials for IBS.
Methods

MEDLINE, EMBASE and the Cochrane central register of controlled trials
were searched to identify randomized controlled trials (RCTs) comparing pharmacological therapies with placebo in adult IBS patients. Studies reported either global assessment of IBS symptom cure or improvement or abdominal pain cure or improvement. Data were extracted as intention-totreat analyses with drop-outs assumed to be treatment failures and pooled using a random-effects model. Proportion of placebo patients experiencing symptom improvement or resolution was reported with a 95% confidence interval (CI). Effect of trial characteristics on magnitude of placebo response was examined.
Results
In all, 73 RCTs were eligible, including 8364 patients with IBS allocated to placebo. Pooled placebo response rate across all RCTs was 37.5% (95% CI 34.4-40.6%). Rates were higher in European RCTs, RCTs that used physician-reported outcomes and RCTs using shorter duration of therapy.
Conclusions
Placebo response rates across RCTs of pharmacological therapies in IBS were high. Future research should identify patient characteristics predicting placebo response.
Aliment Pharmacol Ther 2010; 32: 144-158 INTRODUCTION Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder consisting of abdominal pain in association with a disturbance in bowel habit. 1 The condition follows a chronic relapsing and remitting course. 2, 3 Sufferers represent a significant burden to the health service for reasons of consumption of medical resources, such as consultations in primary and secondary care, [3] [4] [5] [6] investigations, 7 drugs 8 and unnecessary surgical procedures. 9 Despite evidence from recent meta-analyses demonstrating that some pharmaceutical agents, including antispasmodic drugs, peppermint oil, antidepressants and drugs acting on the 5-hydroxytryptamine (5-HT) receptor are of benefit for the treatment of IBS in the shortterm, [10] [11] [12] there is no medical intervention proven to alter the long-term natural history of the condition and there is no agreement on a gold-standard for the treatment of IBS. As a result, whenever a new pharmaceutical agent is developed for IBS, it is compared with placebo in a randomized controlled trial (RCT). There is no structural abnormality that can be corrected by successful therapy and response to treatment is therefore assessed by improvement in symptoms. This is a subjective outcome and, in an effort to standardize research, the Rome foundation has made recommendations as to how best to assess response to therapy in treatment trials conducted in IBS and the other functional GI disorders. 13 Evidence from the systematic review literature suggests that a significant proportion of patients assigned to placebo will respond to therapy, even in RCTs of therapies for organic GI conditions such as inflammatory bowel disease or peptic ulcer, where mucosal or ulcer healing are the outcomes of interest. 14, 15 In functional GI disorders, where trial endpoints are likely to be less tangible than this, the placebo response rate may be even higher. However, despite the fact that there have been numerous published RCTs of pharmacological therapies in IBS, this issue has not been well studied. This is important, as high placebo response rates will statistically reduce the possibility of seeing a positive impact of active therapy and RCTs should be designed to minimize placebo response. We have therefore conducted a systematic review and meta-analysis to assess the magnitude of the placebo response rate in treatment trials of IBS and have examined trial characteristics and features of design that may influence this.
MATERIALS AND METHODS
Search strategy and trial selection
Studies were identified through a search developed to inform an updated monograph on the management of IBS for the American College of Gastroenterology. 16 A search of the medical literature was conducted using MEDLINE (1950 to January 2010), EMBASE (1980 to January 2010) and the Cochrane central register of controlled trials (2009). Randomized controlled trials examining the effect of pharmacological therapies in adult patients (over the age of 16 years) with IBS were eligible for inclusion (Box 1). The first period of cross-over RCTs was also eligible for inclusion. In the case of all RCTs, the control arm was required to receive placebo. Duration of therapy had to be at least 7 days. The diagnosis of IBS could be based on either a physician's opinion or symptom-based diagnostic criteria, supplemented by the results of investigations to exclude organic disease, where trials deemed this necessary. Trials had to report either a global assessment of IBS symptom cure or improvement or abdominal pain cure or improvement, after completion of therapy, preferably as reported by the patient, but if this was not recorded, then as documented by the investigator or via questionnaire data.
Where RCTs included patients with other functional GI disorders or did not report these types of dichotomous data, but were otherwise eligible for inclusion in the systematic review, we attempted to contact the original investigators to obtain further information. Placebo-controlled trials in irritable bowel syndrome were identified with the terms irritable bowel syndrome and functional diseases, colon [both as medical subject heading (MeSH) and free text terms] and IBS, spastic colon, irritable colon and functional adj5 bowel (as free text terms). These were combined using the set operator AND with studies identified with the terms: parasympatholytics, scopolamine, trimebutine, muscarinic antagonists, butylscopolammonium bromide, psychotropic drugs, antidepressive agents, antidepressive agents (tricyclic), desipramine, imipramine, trimipramine, doxepin, dothiepin, nortriptyline, amitriptyline, selective serotonin re-uptake inhibitors, paroxetine, sertraline, fluoxetine, citalopram, venlafaxine, serotonin antagonists, serotonin agonists, cisapride, receptors (serotonin, 5-HT 3 ) and receptors (serotonin, 5-HT 4 ) (both as MeSH terms and free text terms), and the following free text terms: spasmolytics, spasmolytic agents, antispasmodics, mebeverine, alverine, pinaverium bromide, otilonium bromide, cimetropium bromide, hyoscine butyl bromide, butylscopolamine, peppermint oil, colpermin, 5-HT 3 , 5-HT 4 , alosetron, cilansetron, ramosetron, tegaserod and renzapride.
There were no language restrictions and abstracts of the papers identified by the initial search were evaluated by the lead reviewer for appropriateness to the study question and all potentially relevant papers were obtained and evaluated in detail. Foreign language papers were translated where necessary. Abstract books of conference proceedings between 2001 and 2009 were handsearched to identify potentially eligible RCTs published only in abstract form. We also contacted pharmaceutical companies and searched the Food and Drug Administration Agency (FDA) website to obtain data from unpublished RCTs. The bibliographies of all identified relevant trials were used to perform a recursive search of the literature. Articles were independently assessed by two reviewers using pre-designed eligibility forms, according to the prospectively defined eligibility criteria. Any disagreement between investigators was resolved by consensus.
Outcome assessment
The primary outcome assessed was the magnitude of the placebo response rate, in terms of improvement in, or resolution of, global IBS symptoms or abdominal pain, in all RCTs of pharmacological therapies conducted in IBS after cessation of therapy. Secondary outcomes included assessing placebo response rate according to various trial characteristics (see below).
Data extraction
All data were extracted independently by two reviewers on to a Microsoft Excel spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA) as dichotomous outcomes (global IBS symptoms absent or improved, or abdominal pain absent or improved in the placebo arms of the included RCTs) (Box 2). In addition, the following clinical data were extracted for each trial: year of publication, geographical location, setting (primary, secondary, or tertiary care), number of centres, criteria used to define IBS, IBS subtype according to predominant stool pattern reported by the patient (diarrhoea-predominant, constipation-predominant or alternating bowel habit), dosing schedule of the placebo, duration of therapy, proportion of trial patients receiving placebo, active pharmacological therapy used, primary outcome measure used to define symptom improvement or cure following therapy (patient-vs. physician-reported and global IBS symptoms vs. abdominal pain or discomfort), whether the method used to generate the randomization schedule was stated, whether the method of concealment of allocation was stated and overall trial quality (assessed using the Jadad scale, Box 3). 17 Data were extracted as intention-to-treat analyses, with all drop-outs assumed to be treatment failures, wherever trial reporting allowed this.
Data synthesis and statistical analysis Data were pooled using a random-effects model, to give a more conservative estimate of the magnitude of the placebo response rate, allowing for any heterogeneity between trials. 18 Outcomes were expressed as the pooled proportion of patients assigned to placebo with global IBS symptoms or abdominal pain absent or improved after completion of therapy, with a 95% confidence interval (CI). The results of individual RCTs can be diverse and this inconsistency within a single meta-analysis can be quantified with a statistical test of heterogeneity to assess whether the variation across trials is caused by true heterogeneity or chance. This quantity is termed I 2 and its value ranges from 0% to 100%, with 0% representing no observed heterogeneity and larger values indicating increasing heterogeneity. A value below 50% was chosen to represent low levels of heterogeneity. 19 Subgroup analyses were conducted according to year of publication, geographical location, trial setting, single vs. multi-centre trials, criteria used to define IBS, predominant stool pattern reported by the patient, dosing schedule of the placebo, duration of therapy, proportion of trial patients receiving placebo, active pharmacological therapy used, primary outcome measure used to define symptom improvement or cure following therapy (patient vs. physician-reported and global IBS symptoms vs. abdominal pain or discomfort), whether method of randomization or concealment of allocation was reported and trial quality according to the Jadad scale. We did not perform meta-regression in this systematic review and meta-analysis, but rather subgroup analyses according to individual trial characteristics because the former technique evaluates the average of patient characteristics within each trial, and these summary data may misrepresent individual patients within each treatment arm. The technique is therefore vulnerable to giving spurious results due to the ecological fallacy. 20 STATSDIRECT version 2.4.4 (StatsDirect Ltd, Sale, Cheshire, UK) was used to generate Forest plots of the pooled proportions of patients assigned to placebo with global IBS symptoms or abdominal pain absent or improved after completion of therapy, with 95% confidence intervals. Pooled placebo response rates were compared between the pre-defined subgroups using the Cochran Q statistic to assess for any heterogeneity between placebo response rates for the different subgroup analyses we conducted and, because of multiple analyses, a P value of <0.01 was considered statistically significant.
RESULTS
The search strategy generated 3383 citations of which 177 appeared to be relevant to the systematic review and were retrieved for further assessment ( Figure 1 ). Of these 177 RCTs, 104 were excluded for various reasons leaving 73 eligible trials, containing 8364 individuals with IBS who were randomized to receive placebo. Five of these RCTs were published in abstract form only 73-75, 82, 83 and data from two placebo-controlled trials of tegaserod in IBS (B307 and B351) were published in a single document on the FDA website. 84 We contacted original investigators in seven of the studies to clarify data or obtain supplementary information. 42, 49, 72, 82, 83, 85, 87 Agreement between reviewers for assessment of trial eligibility was good (kappa statistic = 0.90). Characteristics of individual RCTs, including the magnitude of the placebo response in each trial, are provided in Table 1 .
Placebo response rate in all trials
The pooled placebo response rate in the 73 RCTs we identified was 37.5% (95% CI 34.4% to 40.6%), with considerable heterogeneity between trials (I 2 = 86.2%,
The placebo response rate in individual RCTs varied from 0% in two trials 21, 23 to 91.7%
(Figure 2).
Placebo response rate according to year of publication, trial location, setting and number of centres Trials were divided into those published before 1999 and those published in 1999 or later, as accepted endpoints for evaluating the success of therapy in IBS treatment trials changed around this point in time. There was, however, no significant difference in placebo response rates 
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M Me et ta a--a an na al ly ys si is s: : p pl la ac ce eb bo o r re es sp po on ns se e r ra at te e i in n t th he e i ir rr ri it ta ab bl le e b bo ow we el l s sy yn nd dr ro om me e Aliment Pharmacol Ther 2010; 32: 144-158between these two time periods (Cochran Q = 0.60, P = 0.44) ( However, the number of Asian and Middle Eastern studies was low (n = 6 and n = 4 respectively) and the differences observed among Asian, Middle-Eastern and North American RCTs were not statistically significant (Table 2) . When the effect of trial setting and number of centres was examined, pooled placebo response rate was very similar in RCTs based in secondary and tertiary care, and in single and multi-centre trials, with no statistically significant difference detected (Cochran Q = 0.08, P = 0.78 for both analyses) ( Table 2) . Placebo response rate according to criteria and symptom data used to define response There were only four RCTs that used a physicianreported outcome to define response to therapy 34, 36, 37, 56 and the pooled placebo response rate was significantly higher in these trials compared with those that used a patient-reported outcome (53.0% vs. 37.4%, Cochran Q = 7.8, P = 0.005) ( Table 2 ). In terms of symptom data used to define response, majority of studies used improvement or relief of global IBS symptoms, although 13 used improvement or relief of abdominal pain or discomfort. There was no significant difference in pooled placebo response rate according to the symptom data used to define response (Cochran Q = 0.6, P = 0.43) ( M Me et ta a--a an na al ly ys si is s: : p pl la ac ce eb bo o r re es sp po on ns se e r ra at te e i in n t th he e i ir rr ri it ta ab bl le e b bo ow we el l s sy yn nd dr ro om me e Aliment Pharmacol Ther 2010; 32: 144-158 à Iteration of Rome criteria not specified.
M , but not in trials using 5-8 weeks of therapy (39.8%, Cochran Q = 0.8, P = 0.37) ( Table 2) . 26 , 31, 45, 46, 48-50, 52, 68, 69, 85 A majority of trials assigned patients to active therapy or placebo in a 1:1 ratio, and pooled placebo response rate was higher in these RCTs compared with trials where fewer patients received placebo than active therapy, 42, 59-61, 64, 70, 71, 76, 77, 82-87 although this difference was not statistically significant (Cochran Q = 2.3, P = 0.13) ( Table 2) .
Placebo response rate according to active pharmacological therapy used Antispasmodic drugs were the active pharmacological agent used in the greatest number of trials. 21, 22, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [54] [55] [56] [57] Pooled placebo response rates were the highest in RCTs that used antispasmodics or mixed 5-HT 3 antagonists ⁄ 5-HT 4 agonists (45.0% for both). Whilst there was a trend for the observed response rate to be higher in RCTs that used antispasmodics compared with those using peppermint oil, 5-HT 3 antagonists or 5-HT 4 agonists, these differences were not statistically significant (Cochran Q = 4.5, P = 0.03 for peppermint oil and Cochran Q = 3.1, P = 0.08 for both 5-HT 3 antagonists and 5-HT 4 agonists) ( Table 2 ). There was also a trend for the response rate to be higher in RCTs that used mixed 5-HT 3 antagonists ⁄ 5-HT 4 agonists compared with those that used peppermint oil, but again this difference did not reach statistical significance (Cochran Q = 3.2, P = 0.07) ( Table 2) .
Placebo response rate according to reporting of method used to generate the randomization schedule or to conceal allocation A majority of RCTs did not report either of these features of their design. Pooled placebo response rate was slightly lower in trials that stated the method used to generate the randomization schedule, but this difference was not statistically significant (Cochran Q = 1.4, P = 0.24) ( Table 2 ). The pooled placebo response rate was almost identical when RCTs were subgrouped according to whether or not the method used to conceal treatment allocation was reported.
Placebo response rate according to trial quality Most RCTs scored 4 or more on the Jadad scale. When pooled placebo response rates according to trial quality were assessed, these were the highest in those with a score of 3 (40.0%), but the response rate was not significantly lower in studies with a score of 4 (37.8%, Cochran Q = 0.15, P = 0.70) or 5 (36.0%, Cochran Q = 0.51, P = 0.47).
DISCUSSION
The present systematic review and meta-analysis of placebo-controlled randomized trials conducted in IBS patients has demonstrated a pooled placebo response rate of 37.5%. The rate was significantly higher in European RCTs compared with those conducted in Asia, the Middle-East or North America, in trials with a treatment duration of 1-4 weeks compared with those that used 8 weeks or more of therapy, and in RCTs that used a physician-reported outcome to define response to therapy compared with those that used a patient-reported endpoint, although in the latter case, there were only four studies that used a physician-reported outcome that provided data for the analysis.
Pooled placebo response rates were generally higher in RCTs using clinical criteria to define the presence of IBS, compared with those that used the Rome I or II criteria, trials that used a three times daily dosing schedule, trials that assigned patients to placebo or active therapy in a 1:1 ratio, trials of antispasmodics and mixed 5-HT 3 antagonists ⁄ 5-HT 4 agonists and trials of lower quality according to the Jadad scale, but none of these differences reached formal statistical significance. Specific features of RCT design such as trial setting, number of involved centres, predominant stool pattern of recruited patients, as well as whether or not investigators reported the method used to generate the randomization schedule and to conceal treatment allocation appeared to have little effect on pooled placebo response rates in our analyses, nor did the year of publication of the trial. Strengths of the present study include the search strategy, which was exhaustive and the fact that we contacted original investigators to obtain supplementary data in some cases, to maximize the number of identified RCTs providing data for these analyses. We assessed the impact of individual trial characteristics on pooled placebo response rates in subgroup analyses. We also performed an intention-to-treat analysis, where all dropouts were assumed to be treatment failures and used a random effects model to provide a more conservative estimate of the pooled placebo response rate, meaning that the magnitude of this effect is unlikely to have been overestimated. Weaknesses of the study include the fact that there was statistically significant heterogeneity when trial data were pooled, which was not explained by any of our subgroup analyses, and the fact that without access to individual patient data, it is difficult to draw any conclusions about specific patient characteristics that may have contributed to the findings of our study.
A previously published systematic review and metaanalysis has examined this issue. 93 The authors identified 45 placebo-controlled trials, containing 3352 individuals with IBS who were randomized to receive placebo. They reported a placebo response rate of 40% when data for all eligible trials were pooled. The response rate was significantly lower in studies that used the Rome criteria to define the presence of IBS, but there were no other features of the studies identified that they examined, including trial duration, score on the Jadad scale and type of active pharmacological therapy, which predicted placebo response rate. There are several limitations of this study. First, there has been a considerable amount of data published in the 5 years since this meta-analysis was conducted. Secondly, the authors included RCTs of therapies for IBS that are not accepted as conventional treatments for the condition, such as activated charcoal, loxiglumide and naloxone. Thirdly, they included crossover studies in which data extraction according to initial treatment allocation was not possible. Finally, they missed eligible studies that were published and available at the time their meta-analysis was conducted. The present study therefore provides new and important information about the magnitude of the placebo response rate in IBS, as well as examining a larger number of trial characteristics and features of design that may influence this.
The finding that placebo response rates were significantly higher in RCTs conducted in European populations is novel. Possible explanations for this are speculative, but it may be that there are cultural differences that influence the magnitude of the placebo effect. The fact that trials with a duration of therapy of between 1 and 4 weeks reported a significantly larger placebo effect than trials using more than 8 weeks is interesting and suggests that any observed benefit of placebo in the treatment of IBS may ameliorate over time. The trend towards a higher placebo response rate seen with an increase in dosing schedule is a phenomenon that has also been described when data from healing rates in duodenal ulcer trials were examined.
14 There is evidence from the systematic review literature that RCTs that do not report the method used to generate the randomization schedule and to conceal allocation tend to overestimate the efficacy of the active therapy. 94 It could therefore be expected that placebo response rates would be lower in trials that did not report these features of their design and it is therefore interesting to note that in our analyses, these had no statistically significant effect on the magnitude of the placebo response. The number of IBS patients achieving response or remission of their symptoms with placebo in this study appears to be somewhere between one in two and one in three. This information is important for the conduct of future RCTs in the condition, as it may be helpful in informing power calculations on which to base trial recruitment. Recent trials of renzapride and citalopram in IBS both failed to demonstrate any significant benefit of these drugs, 68, 95 partly because of the high response rates observed in the placebo arms of the trials, which meant that the studies were underpowered to detect a statistically significant difference, and in the case of renzapride, led the pharmaceutical company that had developed the drug to abandon further investment in its clinical development. 96 Trials that use a longer duration of treatment and use medication given once or twice daily might be expected to reduce the placebo response rate and may have a better ability to demonstrate the benefit of active therapy.
In conclusion, our systematic review and meta-analysis has demonstrated a pooled placebo response rate in all available RCTs of pharmacological therapies in IBS of 37.5%. Future research should concentrate on identifying patient characteristics that predict such a response to treatment, perhaps using trial data at the individual patient level.
